HI homepage

Alan Matsumoto, MD, FSIR, FACR, FAHA, Chairman of Board for the American College of Radiology, professor of radiology and chair of the Department of Radiology, at the University of Virginia, explains ACR support for the Radiology Outpatient Ordering Transmission (ROOT) Act bill in Congress that calls for appropriate use criteria to be used instead of prior authorization.

Alan Matsumoto, MD, chair of the American College of Radiology, explains ACR support for the Radiology Outpatient Ordering Transmission (ROOT) Act in Congress. 

Novel shielding device provides more radiation protection during mammograms.

Experts are hopeful their device can address some of the shortcomings of currently used shielding methods. 

ovaries ovarian cancer

The method targets cancer stem cells, which are highly tumorigenic and known to play a significant role in relapse, cancer spread and treatment resistance.

Lunit AI detects interval breast cancer missed by radiologists

Considering the often-aggressive nature of interval breast cancer, the findings could represent a significant step toward improving patient outcomes, authors of a new research paper suggest.

technologist MRI rad tech radiologic radiology

The American Registry Of Radiologic Technologists says the new offering addresses growing demand for magnetic resonance imaging.

AdventHealth Orlando Hospital is ranked No. 1 on the 2025 U.S. News Honor Roll for best hospitals in America list.

Hospitals are awarded Honor Roll points if they rank in one or more of the 15 specialties that U.S. News evaluates, and in one or more of the 22 procedures or conditions for patient outcomes.

Around the web

RadNet Chaiman and CEO Howard Berger, MD, explains why the company has invested tens of millions into DeepHealth to rapidly build up a new business model. 

 

Thanks to AI, clinicians can use mammograms to do a lot more than identify signs of breast cancer. Researchers explored data from nearly 50,000 patients, presenting their findings in Heart.

A new analysis is prompting questions regarding how rigorously many of the AI-enabled tools approved by the U.S. Food and Drug Administration are evaluated prior to their clearance.